A systematic review and meta-analysis of cancer patients affected by a novel coronavirus
AffiliationTransitional year residency, Department of Internal Medicine, Henry Ford Hospital, Detroit, MI 48202, United States.
MetadataShow full item record
AbstractBackground: Cancer patients with COVID-19 disease have been reported to have double the case fatality rate of the general population. Materials and methods: A systematic search of PubMed/MEDLINE, Embase, Cochrane Central, Google Scholar, and MedRxiv was done for studies on cancer patients with COVID-19. Pooled proportions were calculated for categorical variables. Odds ratio and forest plots were constructed for both primary and secondary outcomes. The random-effects model was used to account for heterogeneity between studies. Results: This systematic review of 31 studies and meta-analysis of 181,323 patients from 26 studies involving 23,736 cancer patients is the largest meta-analysis to the best of our knowledge assessing outcomes in cancer patients affected by COVID-19. Our meta-analysis shows that cancer patients with COVID-19 have a higher likelihood of death (odds ratio, OR 2.54), which was largely driven by mortality among patients in China. Cancer patients were more likely to be intubated, although ICU admission rates were not statistically significant. Among cancer subtypes, the mortality was highest in hematological malignancies (OR 2.43) followed by lung cancer (OR 1.8). There was no association between receipt of a particular type of oncologic therapy and mortality. Our study showed that cancer patients affected by COVID-19 are a decade older than the normal population and have a higher proportion of co-morbidities. There was insufficient data to assess the association of COVID-directed therapy and survival outcomes in cancer patients. Despite the heterogeneity of studies and inconsistencies in reported variables and outcomes, these data could guide clinical practice and oncologic care during this unprecedented global health pandemic. Conclusion: Cancer patients with COVID-19 disease are at increased risk of mortality and morbidity. A more nuanced understanding of the interaction between cancer-directed therapies and COVID-19-directed therapies is needed. This will require uniform prospective recording of data, possibly in multi-institutional registry databases. Keywords: COVID-19; cancer; chemotherapy; meta-analysis; radiotherapy.
CitationVenkatesulu BP, Chandrasekar VT, Girdhar P, Advani P, Sharma A, Elumalai T, et al. A systematic review and meta-analysis of cancer patients affected by a novel coronavirus. medRxiv. 2020.
- Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis.
- Authors: Huang I, Pranata R
- Issue date: 2020
- Impact of COVID -19 in cancer patients on severity of disease and fatal outcomes: A systematic review and meta-analysis.
- Authors: Salunke AA, Nandy K, Pathak SK, Shah J, Kamani M, Kottakota V, Thivari P, Pandey A, Patel K, Rathod P, Bhatt S, Dave P, Pandya S
- Issue date: 2020 Sep - Oct
- Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies.
- Authors: Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M
- Issue date: 2020 Jun 8
- Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies.
- Authors: Armstrong RA, Kane AD, Cook TM
- Issue date: 2020 Oct
- Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project).
- Authors: Juul S, Nielsen N, Bentzer P, Veroniki AA, Thabane L, Linder A, Klingenberg S, Gluud C, Jakobsen JC
- Issue date: 2020 May 9